市場調査レポート
商品コード
1087347

肺水腫治療の世界市場:2022年~2026年

Global Pulmonary Edema Therapeutics Market 2022-2026

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
肺水腫治療の世界市場:2022年~2026年
出版日: 2022年05月31日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の肺水腫治療の市場規模は、2022年から2026年の間に3億3,945万米ドル成長し、予測期間中は3.06%のCAGRで成長する見込みです。

同市場は、危険因子の高い有病率、老年人口の増加、肺水腫に関する意識の高まりなどに牽引されています。

当レポートでは、肺水腫治療の世界市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題、および約25のベンダーをカバーする分析を提供しています。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場のエコシステム

第3章 市場規模

  • 市場の定義
  • 市場セグメント分析
  • 2021年の市場規模
  • 市場の見通し:2021年から2026年の予測

第4章 ファイブフォース分析

  • ファイブフォースまとめ
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

第5章 市場セグメンテーション:タイプ別

  • 市場セグメント
  • タイプ別の比較
  • 心原性肺水腫:市場規模と予測(2021年~2026年)
  • 非心原性肺水腫:市場規模と予測(2021年~2026年)
  • タイプ別の市場機会

第6章 顧客情勢

  • 顧客情勢の概要

第7章 地域別情勢

  • 地域別セグメンテーション
  • 地域別の比較
  • 北米:市場規模と予測(2021年~2026年)
  • 欧州:市場規模と予測(2021年~2026年)
  • アジア:市場規模と予測(2021年~2026年)
  • その他の地域:市場規模と予測(2021年~2026年)
  • 米国:市場規模と予測(2021年~2026年)
  • ドイツ:市場規模と予測(2021年~2026年)
  • 英国:市場規模と予測(2021年~2026年)
  • 中国:市場規模と予測(2021年~2026年)
  • カナダ:市場規模と予測(2021年~2026年)
  • 地域情勢別の市場機会

第8章 推進要因、課題、および動向

  • 市場推進要因
  • 市場の課題
  • 推進要因と課題の影響
  • 市場動向

第9章 ベンダー情勢

  • 概要
  • ベンダー情勢
  • 混乱の状況
  • 業界のリスク

第10章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • AbbVie Inc.
  • ADVANZ PHARMA Corp.
  • Apotex Inc.
  • Bausch Health Companies Inc.
  • Johnson and Johnson
  • Lupin Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

第11章 付録

目次
Product Code: IRTNTR73579

Technavio has been monitoring the pulmonary edema therapeutics market and it is poised to grow by $ 339.45 mn during 2022-2026, accelerating at a CAGR of 3.06% during the forecast period. Our report on the pulmonary edema therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the high prevalence of risk factors, an increasing geriatric population, and growing awareness about pulmonary edema.

The pulmonary edema therapeutics market analysis includes type segment and geographic landscape.

Technavio's pulmonary edema therapeutics market is segmented as below:

By Type

  • Cardiogenic pulmonary edema
  • Non-cardiogenic pulmonary edema

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the increasing use of biomarkers for disease diagnosis as one of the prime reasons driving the pulmonary edema therapeutics market growth during the next few years. Also, strategic alliances and increase in funding for research on respiratory diseases will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on pulmonary edema therapeutics market covers the following areas:

  • Pulmonary edema therapeutics market sizing
  • Pulmonary edema therapeutics market forecast
  • Pulmonary edema therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pulmonary edema therapeutics market vendors that include AbbVie Inc., ADVANZ PHARMA Corp., Apotex Inc., Bausch Health Companies Inc., CHIESI Farmaceutici SpA, CMP Pharma Inc., Johnson and Johnson, Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and Validus Pharmaceuticals LLC. Also, the pulmonary edema therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
  • Exhibit 06: Executive Summary - Chart on Incremental Growth
  • Exhibit 07: Executive Summary - Data Table on Incremental Growth
  • Exhibit 08: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 09: Parent market
  • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021-2026
  • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

  • 4.1 Five forces summary
  • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
  • 4.2 Bargaining power of buyers
  • Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
  • 4.3 Bargaining power of suppliers
  • Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
  • 4.4 Threat of new entrants
  • Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
  • 4.5 Threat of substitutes
  • Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
  • 4.6 Threat of rivalry
  • Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
  • 4.7 Market condition
  • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Type

  • 5.1 Market segments
  • Exhibit 24: Chart on Type - Market share 2021-2026 (%)
  • Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
  • 5.2 Comparison by Type
  • Exhibit 26: Chart on Comparison by Type
  • Exhibit 27: Data Table on Comparison by Type
  • 5.3 Cardiogenic pulmonary edema - Market size and forecast 2021-2026
  • Exhibit 28: Chart on Cardiogenic pulmonary edema - Market size and forecast 2021-2026 ($ million)
  • Exhibit 29: Data Table on Cardiogenic pulmonary edema - Market size and forecast 2021-2026 ($ million)
  • Exhibit 30: Chart on Cardiogenic pulmonary edema - Year-over-year growth 2021-2026 (%)
  • Exhibit 31: Data Table on Cardiogenic pulmonary edema - Year-over-year growth 2021-2026 (%)
  • 5.4 Non-cardiogenic pulmonary edema - Market size and forecast 2021-2026
  • Exhibit 32: Chart on Non-cardiogenic pulmonary edema - Market size and forecast 2021-2026 ($ million)
  • Exhibit 33: Data Table on Non-cardiogenic pulmonary edema - Market size and forecast 2021-2026 ($ million)
  • Exhibit 34: Chart on Non-cardiogenic pulmonary edema - Year-over-year growth 2021-2026 (%)
  • Exhibit 35: Data Table on Non-cardiogenic pulmonary edema - Year-over-year growth 2021-2026 (%)
  • 5.5 Market opportunity by Type
  • Exhibit 36: Market opportunity by Type ($ million)

6 Customer Landscape

  • 6.1 Customer landscape overview
  • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

  • 7.1 Geographic segmentation
  • Exhibit 38: Chart on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibit 39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
  • 7.2 Geographic comparison
  • Exhibit 40: Chart on Geographic comparison
  • Exhibit 41: Data Table on Geographic comparison
  • 7.3 North America - Market size and forecast 2021-2026
  • Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
  • Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
  • 7.4 Europe - Market size and forecast 2021-2026
  • Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
  • 7.5 Asia - Market size and forecast 2021-2026
  • Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
  • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
  • Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • 7.7 US - Market size and forecast 2021-2026
  • Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
  • Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
  • Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
  • Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
  • 7.8 Germany - Market size and forecast 2021-2026
  • Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
  • Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
  • Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
  • Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
  • 7.9 UK - Market size and forecast 2021-2026
  • Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
  • Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
  • Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
  • Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)
  • 7.10 China - Market size and forecast 2021-2026
  • Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
  • Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
  • Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
  • Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
  • 7.11 Canada - Market size and forecast 2021-2026
  • Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)
  • 7.12 Market opportunity By Geographical Landscape
  • Exhibit 78: Market opportunity By Geographical Landscape ($ million)

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers
  • 8.2 Market challenges
  • 8.3 Impact of drivers and challenges
  • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview
  • 9.2 Vendor landscape
  • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
  • 9.3 Landscape disruption
  • Exhibit 81: Overview on factors of disruption
  • 9.4 Industry risks
  • Exhibit 82: Impact of key risks on business

10 Vendor Analysis

  • 10.1 Vendors covered
  • Exhibit 83: Vendors covered
  • 10.2 Market positioning of vendors
  • Exhibit 84: Matrix on vendor position and classification
  • 10.3 AbbVie Inc.
  • Exhibit 85: AbbVie Inc. - Overview
  • Exhibit 86: AbbVie Inc. - Product / Service
  • Exhibit 87: AbbVie Inc. - Key offerings
  • 10.4 ADVANZ PHARMA Corp.
  • Exhibit 88: ADVANZ PHARMA Corp. - Overview
  • Exhibit 89: ADVANZ PHARMA Corp. - Business segments
  • Exhibit 90: ADVANZ PHARMA Corp. - Key offerings
  • Exhibit 91: ADVANZ PHARMA Corp. - Segment focus
  • 10.5 Apotex Inc.
  • Exhibit 92: Apotex Inc. - Overview
  • Exhibit 93: Apotex Inc. - Product / Service
  • Exhibit 94: Apotex Inc. - Key offerings
  • 10.6 Bausch Health Companies Inc.
  • Exhibit 95: Bausch Health Companies Inc. - Overview
  • Exhibit 96: Bausch Health Companies Inc. - Business segments
  • Exhibit 97: Bausch Health Companies Inc. - Key news
  • Exhibit 98: Bausch Health Companies Inc. - Key offerings
  • Exhibit 99: Bausch Health Companies Inc. - Segment focus
  • 10.7 Johnson and Johnson
  • Exhibit 100: Johnson and Johnson - Overview
  • Exhibit 101: Johnson and Johnson - Business segments
  • Exhibit 102: Johnson and Johnson - Key news
  • Exhibit 103: Johnson and Johnson - Key offerings
  • Exhibit 104: Johnson and Johnson - Segment focus
  • 10.8 Lupin Ltd.
  • Exhibit 105: Lupin Ltd. - Overview
  • Exhibit 106: Lupin Ltd. - Product / Service
  • Exhibit 107: Lupin Ltd. - Key news
  • Exhibit 108: Lupin Ltd. - Key offerings
  • 10.9 Novartis AG
  • Exhibit 109: Novartis AG - Overview
  • Exhibit 110: Novartis AG - Business segments
  • Exhibit 111: Novartis AG - Key offerings
  • Exhibit 112: Novartis AG - Segment focus
  • 10.10 Pfizer Inc.
  • Exhibit 113: Pfizer Inc. - Overview
  • Exhibit 114: Pfizer Inc. - Product / Service
  • Exhibit 115: Pfizer Inc. - Key news
  • Exhibit 116: Pfizer Inc. - Key offerings
  • 10.11 Sanofi
  • Exhibit 117: Sanofi - Overview
  • Exhibit 118: Sanofi - Business segments
  • Exhibit 119: Sanofi - Key news
  • Exhibit 120: Sanofi - Key offerings
  • Exhibit 121: Sanofi - Segment focus
  • 10.12 Teva Pharmaceutical Industries Ltd.
  • Exhibit 122: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibit 123: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 124: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibit 125: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 126: Teva Pharmaceutical Industries Ltd. - Segment focus

11 Appendix

  • 11.1 Scope of the report
  • 11.2 Inclusions and exclusions checklist
  • Exhibit 127: Inclusions checklist
  • Exhibit 128: Exclusions checklist
  • 11.3 Currency conversion rates for US$
  • Exhibit 129: Currency conversion rates for US$
  • 11.4 Research methodology
  • Exhibit 130: Research methodology
  • Exhibit 131: Validation techniques employed for market sizing
  • Exhibit 132: Information sources
  • 11.5 List of abbreviations
  • Exhibit 133: List of abbreviations

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Type
  • Exhibits6: Executive Summary - Chart on Incremental Growth
  • Exhibits7: Executive Summary - Data Table on Incremental Growth
  • Exhibits8: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits9: Parent market
  • Exhibits10: Market Characteristics
  • Exhibits11: Offerings of vendors included in the market definition
  • Exhibits12: Market segments
  • Exhibits13: Chart on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibits14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibits15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibits16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibits17: Five forces analysis - Comparison between 2021 and 2026
  • Exhibits18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
  • Exhibits19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
  • Exhibits20: Threat of new entrants - Impact of key factors in 2021 and 2026
  • Exhibits21: Threat of substitutes - Impact of key factors in 2021 and 2026
  • Exhibits22: Threat of rivalry - Impact of key factors in 2021 and 2026
  • Exhibits23: Chart on Market condition - Five forces 2021 and 2026
  • Exhibits24: Chart on Type - Market share 2021-2026 (%)
  • Exhibits25: Data Table on Type - Market share 2021-2026 (%)
  • Exhibits26: Chart on Comparison by Type
  • Exhibits27: Data Table on Comparison by Type
  • Exhibits28: Chart on Cardiogenic pulmonary edema - Market size and forecast 2021-2026 ($ million)
  • Exhibits29: Data Table on Cardiogenic pulmonary edema - Market size and forecast 2021-2026 ($ million)
  • Exhibits30: Chart on Cardiogenic pulmonary edema - Year-over-year growth 2021-2026 (%)
  • Exhibits31: Data Table on Cardiogenic pulmonary edema - Year-over-year growth 2021-2026 (%)
  • Exhibits32: Chart on Non-cardiogenic pulmonary edema - Market size and forecast 2021-2026 ($ million)
  • Exhibits33: Data Table on Non-cardiogenic pulmonary edema - Market size and forecast 2021-2026 ($ million)
  • Exhibits34: Chart on Non-cardiogenic pulmonary edema - Year-over-year growth 2021-2026 (%)
  • Exhibits35: Data Table on Non-cardiogenic pulmonary edema - Year-over-year growth 2021-2026 (%)
  • Exhibits36: Market opportunity by Type ($ million)
  • Exhibits37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits38: Chart on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibits39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibits40: Chart on Geographic comparison
  • Exhibits41: Data Table on Geographic comparison
  • Exhibits42: Chart on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibits43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibits44: Chart on North America - Year-over-year growth 2021-2026 (%)
  • Exhibits45: Data Table on North America - Year-over-year growth 2021-2026 (%)
  • Exhibits46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibits47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibits48: Chart on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibits49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibits50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibits51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibits52: Chart on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibits53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibits54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibits55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibits56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibits57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibits58: Chart on US - Market size and forecast 2021-2026 ($ million)
  • Exhibits59: Data Table on US - Market size and forecast 2021-2026 ($ million)
  • Exhibits60: Chart on US - Year-over-year growth 2021-2026 (%)
  • Exhibits61: Data Table on US - Year-over-year growth 2021-2026 (%)
  • Exhibits62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
  • Exhibits63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
  • Exhibits64: Chart on Germany - Year-over-year growth 2021-2026 (%)
  • Exhibits65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
  • Exhibits66: Chart on UK - Market size and forecast 2021-2026 ($ million)
  • Exhibits67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
  • Exhibits68: Chart on UK - Year-over-year growth 2021-2026 (%)
  • Exhibits69: Data Table on UK - Year-over-year growth 2021-2026 (%)
  • Exhibits70: Chart on China - Market size and forecast 2021-2026 ($ million)
  • Exhibits71: Data Table on China - Market size and forecast 2021-2026 ($ million)
  • Exhibits72: Chart on China - Year-over-year growth 2021-2026 (%)
  • Exhibits73: Data Table on China - Year-over-year growth 2021-2026 (%)
  • Exhibits74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibits75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibits76: Chart on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibits77: Data Table on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibits78: Market opportunity By Geographical Landscape ($ million)
  • Exhibits79: Impact of drivers and challenges in 2021 and 2026
  • Exhibits80: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits81: Overview on factors of disruption
  • Exhibits82: Impact of key risks on business
  • Exhibits83: Vendors covered
  • Exhibits84: Matrix on vendor position and classification
  • Exhibits85: AbbVie Inc. - Overview
  • Exhibits86: AbbVie Inc. - Product / Service
  • Exhibits87: AbbVie Inc. - Key offerings
  • Exhibits88: ADVANZ PHARMA Corp. - Overview
  • Exhibits89: ADVANZ PHARMA Corp. - Business segments
  • Exhibits90: ADVANZ PHARMA Corp. - Key offerings
  • Exhibits91: ADVANZ PHARMA Corp. - Segment focus
  • Exhibits92: Apotex Inc. - Overview
  • Exhibits93: Apotex Inc. - Product / Service
  • Exhibits94: Apotex Inc. - Key offerings
  • Exhibits95: Bausch Health Companies Inc. - Overview
  • Exhibits96: Bausch Health Companies Inc. - Business segments
  • Exhibits97: Bausch Health Companies Inc. - Key news
  • Exhibits98: Bausch Health Companies Inc. - Key offerings
  • Exhibits99: Bausch Health Companies Inc. - Segment focus
  • Exhibits100: Johnson and Johnson - Overview
  • Exhibits101: Johnson and Johnson - Business segments
  • Exhibits102: Johnson and Johnson - Key news
  • Exhibits103: Johnson and Johnson - Key offerings
  • Exhibits104: Johnson and Johnson - Segment focus
  • Exhibits105: Lupin Ltd. - Overview
  • Exhibits106: Lupin Ltd. - Product / Service
  • Exhibits107: Lupin Ltd. - Key news
  • Exhibits108: Lupin Ltd. - Key offerings
  • Exhibits109: Novartis AG - Overview
  • Exhibits110: Novartis AG - Business segments
  • Exhibits111: Novartis AG - Key offerings
  • Exhibits112: Novartis AG - Segment focus
  • Exhibits113: Pfizer Inc. - Overview
  • Exhibits114: Pfizer Inc. - Product / Service
  • Exhibits115: Pfizer Inc. - Key news
  • Exhibits116: Pfizer Inc. - Key offerings
  • Exhibits117: Sanofi - Overview
  • Exhibits118: Sanofi - Business segments
  • Exhibits119: Sanofi - Key news
  • Exhibits120: Sanofi - Key offerings
  • Exhibits121: Sanofi - Segment focus
  • Exhibits122: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibits123: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibits124: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibits125: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibits126: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibits127: Inclusions checklist
  • Exhibits128: Exclusions checklist
  • Exhibits129: Currency conversion rates for US$
  • Exhibits130: Research methodology
  • Exhibits131: Validation techniques employed for market sizing
  • Exhibits132: Information sources
  • Exhibits133: List of abbreviations